000 01405nam a22002777a 4500
001 00004995
003 ES-MaONT
005 20240704102626.0
008 190423s2018 xxkd|||fst||| 001 0 eng d
040 _aES-MaONT
110 _aErnst & Young
_eEY
_97526
245 0 0 _aWhen data and technology expedite growth, how can dealmaking power the value equation?
_b: 2019 EY M&A Firepower report
260 _bEYGM Limited,
_c2018
300 _a39 p. :
_bgráf., tab..
_c1 documento PDF
336 _atexto (visual)
_2isbdcontent
337 _aelectrónico
_2isbdmedia
338 _arecurso en línea
_brdacarrier
_2rdacarrier
520 _aLife sciences M&A in 2018 was strong but failed to meet market expectations as companies focused on portfolio optimization. New digitally savvy entrants are disrupting the larger health ecosystem – and life sciences companies’ business models. In 2019, life sciences companies must accelerate their dealmaking agendas on two fronts: 1)The creation of focused business models y 2) The acquisition of digital apabilities.
650 7 _aSanidad digital
_92065
653 _abusiness models
653 _adigital
653 _aeHealth
856 4 2 _uhttps://assets.ey.com/content/dam/ey-sites/ey-com/en_gl/topics/life-sciences/life-sciences-pdfs/ey-mergers-and-acquisitions-firepower-report.pdf
_x0
_yAcceso a la publicación
942 _2z
_cINF
999 _c4995
_d4995